Navigation Links
ShangPharma Corporation to Announce First Quarter 2011 Financial Results on May 19, 2011
Date:5/9/2011

SHANGHAI, May 9, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the first quarter 2011 ended March 31, 2011 on May 19, 2011. Management will host a conference call to discuss the results at 8:00am New York Time on May 19, 2011 (8:00pm Beijing time on May 19, 2011).

Conference Call Mr. Michael Hui, founder and Chief Executive Officer, Mr. Kevin Chen, President and Chief Operating Officer, and Mr. William Dai, Chief Financial Officer, will discuss the results and take questions following the prepared remarks.

The dial-in details for the live conference call are as follows:- U.S. Toll Free Number:  

1.888.396.2369- International dial-in number:1.617.847.8710- China Toll Free Number:

10 800 152 1490 (North)10 800 852 1490 (South)- Hong Kong Toll Free Number:

800 96 3844Passcode:

SHPA live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com.

A telephone replay of the call will be available for seven days from May 19, 2011 to May 26, 2011. The dial-in details for the replay are as follows: - U.S. Toll Free Number:

1-888-286-8010- International dial-in number:1-617-801-6888Passcode:

64510327About ShangPharma Corp.ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, contact:ShangPharma CorporationLan Xie, VP of Finance and OperationsE-mail: IR@shangpharma.comChristensenIn New YorkKimberly Minarovich,Phone: +1 917-533-3268E-mail: kminarovich@christensenir.comIn Hong KongTip FlemingPhone: +852-9212-0684Email: tfleming@ChristensenIR.com  
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee
2. ShangPharma to Present at the Citibank Global Health Care Conference from March 1 - 3, 2011
3. ShangPharma Announces Fourth Quarter and Fiscal Year 2010 Results
4. ShangPharma Corporation Files 2010 Annual Report on Form 20-F
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. CEL-SCI Corporation Releases Letter to Shareholders
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
11. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really ... cream can be incorporated into the post-surgical treatment plans of a variety of other ... dermaka cream is very effective for bruising and causes a rapid resolution of bruising ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Seema Daulat, a native Texan and University ... Lamar location as of July 13, 2016. , Dr. Daulat earned her Doctorate of ... she regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical ...
(Date:6/23/2016)... ... 23, 2016 , ... SyncDog, Inc. , the leading ... is featured in the current issue of Silicon Review magazine. Silicon ... technology solutions and features them in their magazine. The magazine allows top-level executives ...
(Date:6/23/2016)... ... 23, 2016 , ... The U.S. Supreme Court decision on immigration has significant ... The Senior Citizens League (TSCL) . “President Obama’s executive actions on immigration would ... who worked in this country illegally, even though the newly - issued green cards ...
Breaking Medicine News(10 mins):